RTW
NEUTRALRTW Biotech Opportunities Provides Update on Kailera Therapeutics
The investment company provides an update on its portfolio company Kailera Therapeutics, a clinical-stage biopharmaceutical firm developing obesity treatments.
RTW Biotech Opportunities Ltd
1.3100USD
-0.57%
Market Cap
434.86M
Volume
78.65k
18% of avg
P/E Ratio
EPS (TTM)
Beta
0.59
Day Range
1.3000p - 1.3200p
52 Week Range
1.0800p1.3100p1.6470p
1.3100p
Upcoming Events
RTW
NEUTRALRTW Biotech Opportunities Ltd Provides Monthly Valuation Update
The investment fund provides its monthly valuation update, reporting a 0.2% increase in net asset value per share for June 2025.
RTW
VERY GOODMerck to Acquire Verona Pharma for $10 Billion, Expanding Chronic Lung Disease Portfolio
The biopharmaceutical company has agreed to be acquired by Merck for $10 billion, a major validation of its COPD treatment Ohtuvayre and an opportunity to expand its reach under Merck's commercial capabilities.
RTW
NEUTRALRTW Biotech Announces Holding Change
The biotech company has announced a change in shareholding, with Tang Capital Partners, LP now holding 4.99% of the company's shares.
RTW
NEUTRALRTW Biotech Provides Update on Corxel Pharmaceuticals Pipeline Progress
The biopharmaceutical investment fund provides an update on the progress of its private portfolio company Corxel Pharmaceuticals, highlighting positive results from a China Phase 2 trial and the initiation of a U.S. Phase 2 trial for its lead obesity drug candidate.
RTW
NEUTRALRTW Biotech Opportunities Ltd Announces Director Share Purchase
The retailer has announced a director has purchased 15,000 shares in the company.
RTW
NEUTRALRTW Biotech Opportunities Ltd Provides Portfolio Updates
The investment company provides updates on its portfolio, including positive clinical data from Taysha Gene Therapies and developments at Rocket Pharmaceuticals and Merus.
RTW
NEUTRALRocket Pharmaceuticals Provides Positive Update on RP-A601 Phase 1 Trial
The investment company provides an update on positive preliminary data from a Phase 1 trial of a gene therapy treatment being developed by one of its portfolio companies.
RTW
NEUTRALRTW Biotech Opportunities Ltd Announces Annual General Meeting
The biotech investment fund announces its upcoming Annual General Meeting, providing details on the event and how shareholders can participate.
RTW
NEUTRALRTW Biotech Opportunities Provides Update on Artios Pharma
The investment company provides an update on its portfolio company Artios Pharma, highlighting positive data from a clinical study of Artios' lead candidate.